Navigation Links
Drug May Help Colitis Patients Avoid Surgery
Date:10/2/2009

Infliximab linked to fewer colectomies in study patients

FRIDAY, Oct. 2 (HealthDay News) -- Treatment with the drug infliximab (Remicade) reduced the need for surgery in ulcerative colitis patients by almost half, a new study found.

Ulcerative colitis causes chronic inflammation of the colon and often leads to surgical removal of the colon (colectomy).

This study included 728 patients who received either an inactive placebo or infliximab for 46 weeks. After one year of follow-up, the researchers found that "treatment with infliximab reduced the need for colectomy by 41 percent compared to patients treated with placebo," lead author and Mayo Clinic gastroenterologist Dr. William Sandborn, said in a Mayo Clinic news release.

The study appears in the October issue of the journal Gastroenterology.

"One of the most feared outcomes for ulcerative colitis patients is surgical removal of the colon. Our research hopes to provide other treatment solutions for patients beyond surgery," Sandborn said.

He provided consulting services for drug maker Centocor during this research. The Mayo Clinic was paid for Sandborn's services.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about ulcerative colitis.



-- Robert Preidt



SOURCE: Mayo Clinic, news release, Sept. 30, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Mouse Study Gives Clues to Colitis
2. New therapeutic targets in the treatment of ulcerative colitis
3. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
4. Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives
5. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
6. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
7. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
8. A rare case of ischemic colitis caused by chronic venous insufficiency
9. Study underway to find an alternative cure for Crohns disease and ulcerative colitis
10. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
11. Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... On Dec. ... the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have ... (MPNs) by going above and beyond the standard of care, demonstrating leadership within the ...
(Date:12/2/2016)... ... ... Advanced Inc., a leading provider of travel therapy and travel nursing across ... Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as Vice ... leadership experience to Advanced Inc. He began his career in finance at Ernst & ...
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... interview of two ostomy patients, standing as living proof that attitude and determination ... digestive diseases and issues that spike around the holidays. This campaign will offer ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Health" in USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized ... fulfilling lives. “We are prolonging life 6 years in the last 3 decades,” ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 According to a ... by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical ... Nephrology, Infectious Diseases) - Forecast to 2021" published ... USD 60.22 Billion in 2016. This market is ... during the forecast period (2016-2021) to reach USD ...
(Date:12/2/2016)...  The Addiction Treatment Advisory Group (ATAG), created ... Pharmacy (AMCP), has released detailed findings on how ... addiction crisis, including through improved access to naloxone ... newly released paper, "The Role of Managed Care ... issues around gaps and barriers to addiction treatment ...
(Date:12/2/2016)... -- Boston Scientific Corporation (NYSE: BSX ) ... assets and capabilities of the Neovasc, Inc., (NASDAQ: ... as well as a 15% equity stake in Neovasc, ... Neovasc advanced biological tissue business makes elements used in ... System. * Upon completion of the transaction, the ...
Breaking Medicine Technology: